Fikadu Tafesse, Ph.D.
- Associate Professor of Molecular Microbiology and Immunology, School of Medicine
- Molecular Microbiology and Immunology Graduate Program, School of Medicine
- Program in Molecular and Cellular Biosciences, School of Medicine
Biography
Dr. Tafesse received his PhD from Utrecht University, The Netherlands. He did his postdoctoral studies at Whitehead Institute for Biomedical Research (MIT) in the lab of Hidde Ploegh where he was an NWO Rubicon fellow, and worked on host-pathogen interaction of viruses, fungi and bacterial toxins. Before joining OHSU, Dr. Tafesse was an Instructor in Medicine, Assistant in Immunology at the Ragon Institute of MGH, Harvard and MIT where he established his research program in Mtb and HIV.
Publications
Publications
Biolayer interferometry for measuring the kinetics of protein–protein interactions and nanobody binding
Nature protocolsA nanobody interaction with SARS-COV-2 Spike allows the versatile targeting of lentivirus vectors
Journal of virologyDelivery of loaded MR1 monomer results in efficient ligand exchange to host MR1 and subsequent MR1T cell activation
Communications BiologyDiverging Maternal and Cord Antibody Functions From SARS-CoV-2 Infection and Vaccination in Pregnancy
Journal of Infectious DiseasesESAT-6 undergoes self-association at phagosomal pH and an ESAT-6-specific nanobody restricts M. tuberculosis growth in macrophages
eLifeEvaluating Humoral Immunity Elicited by XBB.1.5 Monovalent COVID-19 Vaccine
Emerging infectious diseasesTrifunctional fatty acid derivatives
Chemical CommunicationsTrifunctional Sphinganine
ACS chemical biologyAn extended interval between vaccination and infection enhances hybrid immunity against SARS-CoV-2 variants
JCI InsightA global lipid map reveals host dependency factors conserved across SARS-CoV-2 variants
Nature communicationsA lyophilized colorimetric RT-LAMP test kit for rapid, low-cost, at-home molecular testing of SARS-CoV-2 and other pathogens
Scientific ReportsA potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variants
iScienceA Single Dose of ChAdOx1 nCoV-19 Vaccine Elicits High Antibody Responses in Individuals with Prior SARS-CoV-2 Infection Comparable to That of Two-Dose-Vaccinated, SARS-CoV-2-Infection-Naïve Individuals
VaccinesBNT162b2-induced neutralizing and non-neutralizing antibody functions against SARS-CoV-2 diminish with age
Cell ReportsCannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants
Journal of Natural ProductsHigh seroprevalence of anti-SARS-CoV-2 antibodies among Ethiopian healthcare workers
BMC Infectious DiseasesOmicron neutralizing antibody response following booster vaccination compared with breakthrough infection
MedSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific Memory B Cells from Individuals with Diverse Disease Severities Recognize SARS-CoV-2 Variants of Concern
Journal of Infectious DiseasesVaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants
Science ImmunologyCapsid-specific nanobody effects on HIV-1 assembly and infectivity
VirologyCeramide synthase 2 deletion decreases the infectivity of HIV-1
Journal of Biological ChemistryCross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2
Cell ReportsNeutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum
Nature communicationsSphingomyelin biosynthesis is essential for phagocytic signaling during mycobacterium tuberculosis host cell entry
mBioA global lipid map defines a network essential for Zika virus replication
Nature communicationsAlternative splicing of MR1 regulates antigen presentation to MAIT cells
Scientific Reports